Statistics for Oral Tau Aggregation Inhibitor for Alzheimer’s Disease : Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate
Total visits
| views | |
|---|---|
| Oral Tau Aggregation Inhibitor for Alzheimer’s Disease : Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate | 2 |
Total visits per month
| views | |
|---|---|
| June 2025 | 0 |
| July 2025 | 0 |
| August 2025 | 0 |
| September 2025 | 0 |
| October 2025 | 1 |
| November 2025 | 0 |
| December 2025 | 1 |
File Visits
| views | |
|---|---|
| Wischik_et_al_Oral_Tau_Journal_of_Prevention_of_Alzheimers_Disease_vor.pdf | 14 |